Sunshine Biopharma (SBFM) Non-Current Assets (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Non-Current Assets came in at $3.1 million in Q1 2026, down 33.13% YoY from $4.7 million in Q1 2025, and down 2.43% on a QoQ basis from $3.2 million in Q4 2025.
Sunshine Biopharma (SBFM) Non-Current Assets (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 12 years of Non-Current Assets data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 33.13% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 33.13% YoY) and the FY2025 annual result came in at $3.2 million, down 29.79% from the prior year.
- Non-Current Assets slipped to $3.1 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $4.7 million in Q1 2025 to a low of $1642.0 in Q2 2022.
- A 5-year average of $2.6 million and a median of $3.1 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 87.82% — and 2023, when it jumped 140662.06%.
- Tracing SBFM's Non-Current Assets over 5 years: stood at $1.9 million in 2022, then advanced by 27.2% to $2.5 million in 2023, then jumped by 86.98% to $4.6 million in 2024, then retreated by 29.79% to $3.2 million in 2025, then slipped by 2.43% to $3.1 million in 2026.
- The last three Non-Current Assets figures came in at $3.1 million (Q1 2026), $3.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | 2.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.97 Mn |
| Mar 31, 2026 | 3.15 Mn |
| Dec 31, 2025 | 3.23 Mn |
| Sep 30, 2025 | 3.52 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | 4.71 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 2.46 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Mar 31, 2023 | 2.04 Mn |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 3,770.00 |
| Jun 30, 2022 | 1,642.00 |
| Mar 31, 2022 | 3,975.00 |
| Dec 31, 2021 | 7,061.00 |
| Sep 30, 2021 | 10,232.00 |